Acelity Holdings Inc. has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given in the filing, but the offering is valued up to $100 million, though this number is normally just a placeholder. The company intends to file on the New York Stock Exchange (NYSE) but has yet to decide on a symbol.

The underwriters for the offering are JPMorgan, Goldman Sachs, Merrill Lynch, Morgan Stanley, Barclays, Credit Suisse, RBC Capital Markets and UBS Investment Bank.

This is a leading global medical technology company committed to the development and commercialization of advanced wound care and regenerative medicine solutions. Acelity was formed by uniting three organizations — KCI, Systagenix and LifeCell — into its two business segments: Advanced Wound Therapeutics (AWT) and Regenerative Medicine.

The company’s mission is to change the clinical practice of medicine with solutions that speed healing, reduce complications, create economic value and improve patients’ lives, using its negative pressure wound therapy (NPWT) and acellular tissue matrices.

The AWT business is focused on the development and commercialization of advanced devices and advanced wound dressings. The advanced devices business is primarily engaged in marketing several technology platforms, including NPWT, surgical and incision management and epidermal grafting. The Regenerative Medicine business is primarily focused on the development and commercialization of regenerative and reconstructive acellular tissue matrices for use in general and reconstructive surgical procedures to reinforce soft tissue defects.

Acelity is a global company with approximately 29% of its 2014 revenues generated outside the United States, and its products are available in more than 75 countries. A critical component of marketing its portfolio of solutions and services is the company’s sales organization of roughly 1,800 professionals working across multiple care settings and specialties, with about 1,000 based in the United States.

In the filing the company described its finances as:

For the year ended December 31, 2014 and the six months ended June 30, 2015, we generated revenue of $1,866.3 million and $905.7 million, respectively. For the year ended December 31, 2014 and the six months ended June 30, 2014 and 2015, we generated loss from continuing operations of $235.0 million, $200.9 million and $22.2 million, respectively. We generated Adjusted EBITDA of $712.1 million, $322.0 million and $338.7 million for the year ended December 31, 2014 and the six months ended June 30, 2014 and 2015, respectively.

The company intends to use the proceeds from this offering to redeem a portion of its outstanding senior notes and for general corporate purposes.

ALSO READ: Oppenheimer’s 7 Bull Market Leaders to Buy After the Sell-Off

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.